
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Catalent announced the opening of its new clinical supply facility located in the Shiga prefecture of Japan, in response to increased demand for end-to-end services, including primary packaging.
The 6,000 square-meter site will provide flexible clinical supply solutions, serving both local and global biotech and pharmaceutical companies. The facility will work alongside two sites in China and one in Singapore.
Acquired from Teva-Takeda Pharmaceuticals in July 2020, the Shiga site has since undergone significant redevelopment and will also add specialized solutions for the Asia-Pacific markets including Catalent’s FastChain demand-led supply and logistics.






